CARA - キャラ・セラピュ―ティックス （Cara Therapeutics Inc.） キャラ・セラピュ―ティックスCARAのチャート
CARAの企業情報
| symbol | CARA |
|---|---|
| 会社名 | Cara Therapeutics Inc （キャラ・セラピュ―ティックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 キャラ・セラピューティックス（Cara Therapeutics Inc.）は、臨床段階のバイオ医薬品会社である。同社は、カッパオピオイド 受容体に焦点を当てて痛みとかゆみを緩和するように設計された化学物質の開発と商品化に注力する。同社は、体の末梢神経系を標的とする一連の候補製品を開発する。同社は、疼痛およびかゆみを含む重大な病状を治療するための治療薬の発見及び開発に関連する活動を行う。同社の候補製品パイプラインは、急性疼痛と尿毒症性掻痒症の向けのI.V. CR845、急性および慢性疼痛向けのOral CR845、神経因性疼痛および炎症性疼痛向けのCR701を含む。I.V. CR845は急性期診療における急性疼痛の治療を目的とする、末梢κオピオイド受容体アゴニストの注射可能なバージョンである。CR845は、標準的な前臨床モデルにおいて、抗掻痒性または抗かゆみ性を展示する。 キャラ・セラピュ―ティックスは、臨床段階の米国のバイオ医薬品会社。痛みを軽減するための化学物質の開発・商品化に焦点を当てる。主要製品候補は、疼痛緩和を提供する｢IV CR845｣注射薬、外来における急性または慢性疼痛を有する患者の痛みの緩和に｢CR845｣飲み薬、また末梢限定｢CR701｣薬がある。 Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA™ has successfully completed a Phase 2 trial for the treatment of pruritus in patients with CKD and is currently in Phase 2 trials in atopic dermatitis, primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. |
| 本社所在地 | 4 Stamford Plaza 107 Elm Street 9th Floor Stamford CT 06902 USA |
| 代表者氏名 | Derek T. Chalmers デレク・T・チャーマーズ |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 203-406-3700 |
| 設立年月日 | 38169 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 11人 |
| url | www.caratherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cara |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -61.97500 |
| 終値（lastsale） | 20.2 |
| 時価総額（marketcap） | 793667372.8 |
| 時価総額 | 時価総額（百万ドル） 784.23770 |
| 売上高 | 売上高（百万ドル） 2.87400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 653.97170 |
| 当期純利益 | 当期純利益（百万ドル） -34.66900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cara Therapeutics Inc revenues increased from $911K to $2.9M. Net loss increased 8% to $34M. Revenues reflect License and milestone fees revenue increase from $530K to $2.9M. Higher net loss reflects Research and development - Balancing v increase of 9% to $28.7M (expense) Stock-based Compensation in SGA increase of 94% to $2.4M (expense). |
CARAのテクニカル分析
CARAのニュース
Cara Therapeutics, Inc. (CARA) to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022/09/06 13:16:13 Marijuana Stocks
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment…
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022/09/06 11:00:00 GlobeNewswire
STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 24 th Annual Global Investment Conference on Tuesday, September 13, 2022, at 8:30 a.m. ET.
Cara Therapeutics Stock: All Eyes On Korsuva Launch Metrics 2022/09/01 21:03:39 Seeking Alpha
Korsuva has been approved in an indication for which it faces little in the way of competition. Click to read our analysis of Cara Therapeutics stock.
Cara Therapeutics, Inc. (CARA) Announces KOMFORT Data Accepted for Late-Breaking Presentation 2022/08/22 13:14:03 Marijuana Stocks
Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st…
Cara, Vifor''s Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients 2022/08/19 08:52:33 Seeking Alpha
The Swiss Agency for Therapeutic Products (Swissmedic) approved Cara Therapeutics (CARA) and Vifor Fresenius Medical Care Renal Pharma''s Kapruvia…
Tudor Investment Corp Et Al Takes $1.04 Million Position in Cara Therapeutics, Inc. (NASDAQ:CARA) 2021/11/04 10:40:42 Transcript Daily
Tudor Investment Corp Et Al bought a new stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 72,497 shares of the biopharmaceutical companys stock, valued at approximately $1,035,000. Tudor Investment Corp Et Al []
Cara Therapeutics, Inc. (CARA) Announces CEO Transition 2021/11/03 12:56:49 Marijuana Stocks
Cara Therapeutics Announces CEO Transition Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
Cara Therapeutics (NASDAQ:CARA) vs. Arcus Biosciences (NYSE:RCUS) Head-To-Head Comparison 2021/11/03 03:18:41 Transcript Daily
Cara Therapeutics (NASDAQ:CARA) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk. Institutional and Insider Ownership 62.0% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 56.8% []
Cara Therapeutics, Inc. (NASDAQ:CARA) Shares Acquired by Dimensional Fund Advisors LP 2021/11/02 08:48:41 Dakota Financial News
Dimensional Fund Advisors LP lifted its stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 563.8% during the second quarter, Holdings Channel.com reports. The fund owned 420,671 shares of the biopharmaceutical companys stock after purchasing an additional 357,302 shares during the period. Dimensional Fund Advisors LPs holdings in Cara Therapeutics were worth $6,003,000 at the []
Cara Therapeutics Inc. (NASDAQ: CARA) Shares Are Heading Higher 2021/11/01 15:30:00 Marketing Sentinel
In the last trading session, 1.79 million shares of the Cara Therapeutics Inc. (NASDAQ:CARA) were traded, and its beta was 1.09. Most recently the companys share price was $16.83, and it changed around -$0.12 or -0.71% from the last close, which brings the market valuation of the company to $849.07M. CARA currently trades at a Cara Therapeutics Inc. (NASDAQ: CARA) Shares Are Heading Higher Read More »
Cannabis Stock Gainers And Losers From April 9, 2021 2021/04/09 20:43:43 Benzinga
GAINERS: Primo Nutraceuticals (OTC: BUGVF ) shares closed up 33.33% at $0.20 Inner Spirit Holdings (OTC: INSHF ) shares closed up 9.69% at $0.21 Greenlane Holdings (NASDAQ: GNLN ) shares closed up 8.44% at $6.04 EnWave (OTC: NWVCF ) shares closed up 7.44% at $1.30 RIV Capital (OTC: CNPOF ) shares closed up 6.67% at $1.92 Cara Therapeutics (NASDAQ: CARA ) … Full story available on Benzinga.com
Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference 2021/04/07 16:01:00 Benzinga
STAMFORD, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and …
Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options | Investing.com 2021/04/07 13:00:58 Investing.com
Stocks Analysis by Zacks Investment Research covering: Cara Therapeutic. Read Zacks Investment Research's latest article on Investing.com
Illumina, Cara Therapeutics rise; Greenbrier, Paychex fall 2021/04/06 20:23:14 ABC News
Stocks that traded heavily or had substantial price changes Tuesday: Illumina, Cara Therapeutics rise; Greenbrier, Paychex fall
Cannabis Stock Gainers And Losers From April 5, 2021 2021/04/05 21:13:27 Benzinga
GAINERS: BioHarvest Sciences (OTC: CNVCF ) shares closed up 12.8% at $0.45 Emerald Health (OTC: EMHTF ) shares closed up 11.84% at $0.24 Cara Therapeutics (NASDAQ: CARA ) shares closed up 9.52% at $23.82 CV Sciences (OTC: CVSI ) shares closed up 6.52% at $0.49 The Flowr (OTC: FLWPF ) shares closed up 4.58% at $0.26 Australis Capital (OTC: AUSAF ) shares closed up 4.22% at $0.32 Zenabis Global (OTC: ZBISF ) shares closed up 3.99% at $0.10 Zelira Therapeutics (OTC: ZLDAF ) shares closed up 3.84% at $0.05 Neptune Wellness … Full story available on Benzinga.com